bluebird bio, Inc. (NASDAQ:BLUE) Stock Position Boosted by Rhumbline Advisers

Rhumbline Advisers boosted its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 25.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 292,436 shares of the biotechnology company’s stock after acquiring an additional 59,219 shares during the quarter. Rhumbline Advisers’ holdings in bluebird bio were worth $288,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Masters Capital Management LLC bought a new position in bluebird bio in the 4th quarter valued at about $1,380,000. Mirae Asset Global Investments Co. Ltd. grew its position in bluebird bio by 38.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 90,139 shares in the last quarter. Virtu Financial LLC bought a new position in bluebird bio in the 4th quarter valued at about $317,000. HBK Investments L P bought a new position in bluebird bio in the 4th quarter valued at about $2,070,000. Finally, Vestal Point Capital LP bought a new position in shares of bluebird bio during the 4th quarter valued at about $2,967,000. Institutional investors own 87.43% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BLUE. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a research report on Monday, September 16th. StockNews.com began coverage on shares of bluebird bio in a research report on Friday. They set a “sell” rating for the company. Robert W. Baird reduced their price objective on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of bluebird bio in a research report on Thursday, August 15th. Finally, Bank of America reduced their price objective on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.63.

bluebird bio Trading Up 1.4 %

Shares of BLUE stock opened at $0.50 on Friday. bluebird bio, Inc. has a 1 year low of $0.46 and a 1 year high of $5.53. The firm’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $0.97. The firm has a market capitalization of $55.15 million, a P/E ratio of -0.68 and a beta of 0.75. The company has a current ratio of 0.93, a quick ratio of 0.82 and a debt-to-equity ratio of 0.20.

bluebird bio Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.